Spoken Alpha
Sensei Biotherapeutics, Inc.
Sensei Biotherapeutics develops PIKTOR, an oral combination therapy targeting multiple nodes of the PI3K/AKT/mTOR pathway for cancer treatment. The company is advancing PIKTOR in clinical trials for advanced endometrial and HR+/HER2- breast cancer, with additional pipeline programs addressing tumor metabolism and rare metabolic diseases.
Sensei Biotherapeutics, Inc is a Healthcare company operating in Biotechnology with a $18.6M market cap.
SNSE missed consensus EPS by 1.0% in Q1 FY2026, reported Mar 30, 2026.
Behavioral analysis
Disclosures
Extracted from Unknown source, 2026-06-21.
Transcripts
We index calls for roughly 3,000 US-listed companies. If you'd like us to add SNSE, reply to your welcome email and we'll prioritize it.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for SNSE.
$ curl https://api.spokenalpha.com/v1/companies/SNSEFAQ
Spoken Alpha indexes SNSE's earnings call transcripts at https://spokenalpha.com/companies/SNSE. Each call links to attributed speakers and parsed analyst Q&A. Sensei Biotherapeutics, Inc.'s own investor relations page is at https://investors.senseibio.com/.
Sensei Biotherapeutics, Inc. (SNSE) operates in the Healthcare sector (Biotechnology industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q1 FY2026 | 2026-03-30 | $-131.45 | $-0.62 | -100.0% | $0 | — | — | EODHD |
| Q4 FY2025 | 2025-12-30 | $-3.74 | $-4.81 | +22.3% | $0 | — | — | EODHD |
| Q3 FY2025 | 2025-11-13 | $-3.62 | $-0.23 | -100.0% | $-4.9M | — | — | EODHD |
| Q2 FY2025 | 2025-08-04 | $-3.91 | $-0.24 | -100.0% | $0 | — | — | EODHD |
| Q1 FY2025 | 2025-05-06 | $-0.27 | $-0.26 | -4.8% | $0 | — | — | EODHD |
| Q4 FY2024 | 2025-02-25 | $-0.27 | $-0.29 | +5.9% | $544.0K | — | — | EODHD |
| Q3 FY2024 | 2024-11-04 | $-0.29 | $-0.31 | +6.5% | $0 | — | — | EODHD |
| Q2 FY2024 | 2024-08-05 | $-0.28 | $-0.29 | +3.5% | $0 | — | — | EODHD |
| Q1 FY2024 | 2024-05-08 | $-0.32 | $-0.28 | -14.3% | $0 | — | — | EODHD |
| Q4 FY2023 | 2024-02-27 | $-0.30 | $-0.31 | +3.2% | $2.8M | — | — | EODHD |
| Q3 FY2023 | 2023-11-06 | $-0.28 | $-0.34 | +17.6% | $0 | — | — | EODHD |
| Q2 FY2023 | 2023-08-02 | $-0.31 | $-0.33 | +6.1% | $0 | — | — | EODHD |
| Q1 FY2023 | 2023-05-08 | $-0.33 | $-0.36 | +8.3% | $0 | — | — | EODHD |
| Q4 FY2022 | 2023-03-27 | $-0.40 | $-0.40 | 0.0% | $0 | — | — | EODHD |
| Q3 FY2022 | 2022-11-07 | $-0.44 | $-0.37 | -18.9% | $0 | — | — | EODHD |
| Q2 FY2022 | 2022-08-08 | $-0.34 | $-0.39 | +12.8% | $0 | — | — | EODHD |
| Q1 FY2022 | 2022-05-09 | $-0.40 | $-0.35 | -14.3% | $0 | — | — | EODHD |
| Q4 FY2021 | 2022-03-09 | $-0.30 | $-0.34 | +11.8% | $0 | — | — | EODHD |
| Q3 FY2021 | 2021-11-08 | $-0.32 | $-0.24 | -33.3% | $0 | — | — | EODHD |
| Q2 FY2021 | 2021-08-03 | $-0.32 | $-0.29 | -10.3% | $0 | — | — | EODHD |
Source: EODHD. SNSE reported actuals as published; sparse fields render as —.